WE AIM TO IMPROVE PREVENTION, EARLY DIAGNOSIS AND THERAPY BY DEVELOPING NOVEL DRUG DELIVERY NANOPLATFORM
BBS Nanotechnology is a privately held company that develops biocompatible, targeted, nanosystem based delivery platforms of anti-cancer therapeutics, diagnostics and other compounds.
We are developing novel ways for the delivery of active ingredients or diagnostic agent delivery in order to better target already existing or currently developed active compounds, chemotherapy or contras agents. Improved targeting results in improved bioavailability in the affected tissues – this allows better outcomes and less side effects.
By harnessing the controlled flexibility of BBS’ unique chemistry, our platform allows for the selection of optimally targeted nanoparticles to achieve high affinity binding, stability, efficacy and manufacturability.